Harnessing biodiversity for peptide therapeutics

Phylogica  2014  AGM  Presenta7on  

(PYC:ASX)  

For

per

sona

l use

onl

y

       Disclaimer  The   purpose   of   the   presenta.on   is   to   provide   an   update   of   the   business   of   Phylogica   Limited   (ASX:PYC)  [‘Phylogica’].  These  slides  have  been  prepared  as  a  presenta.on  aid  only  and  the  informa.on  they  contain  may  require   further   explana.on   and/or   clarifica.on.   Accordingly,   these   slides   and   the   informa.on   they   contain  should  be  read  in  conjunc.on  with  past  and  future  announcements  made  by  Phylogica  and  should  not  be  relied  upon  as  an  independent  source  of  informa.on.  Please  contact  Phylogica  and/or  refer  to  the  Company's  website  for  further  informa.on.  

The  views  expressed  in  this  presenta.on  contain  informa.on  derived  from  publicly  available  sources  that  have  not  been   independently  verified.  No   representa.on  or  warranty   is  made  as   to   the  accuracy,   completeness  or  reliability  of  the  informa.on.  

Any   forward   looking   statements   in   this   presenta.on   have   been   prepared   on   the   basis   of   a   number   of  assump.ons  which  may  prove  incorrect  and  the  current  inten.ons,  plans,  expecta.ons  and  beliefs  about  future  events   are   subject   to   risks,   uncertain.es   and   other   factors,   many   of   which   are   outside   Phylogica’s   control.  Important   factors   that   could   cause   actual   results   to   differ   materially   from   assump.ons   or   expecta.ons  expressed  or  implied  in  this  presenta.on  include  known  and  unknown  risks.  Because  actual  results  could  differ  materially   to  assump.ons  made  and  Phylogica’s   current   inten.ons,  plans,   expecta.ons  and  beliefs   about   the  future,  you  are  urged  to  view  all  forward  looking  statements  contained  in  this  presenta.on  with  cau.on.  

This   presenta.on   should   not   be   relied   on   as   a   recommenda.on   or   forecast   by   Phylogica.   Nothing   in   this  presenta.on  should  be  construed  as  either  an  offer  to  sell  or  a  solicita.on  of  an  offer  to  buy  or  sell  shares  in  any  jurisdic.on.  

2  

For

per

sona

l use

onl

y

3

2014  Highlights  

§  Successfully  validated  powerful  intracellular  drug  delivery  plaTorm  

§  Iden.fied  ‘Best-­‐in-­‐Class’  Phylomers  for  delivering  drugs  inside  cells  

§  ‘Value-­‐adding’  strategy  to  improve  intracellular  delivery  of  exis.ng  drugs  

§  Launched  proprietary  cancer  programme  (Product  Focus)  

§  Announced  collabora.on  with  Genentech  

For

per

sona

l use

onl

y

Corporate  Snapshot  

4  

 Shareholders   %  B.  Hockings     25  Sietsma  Holdings   8  Bonadido   4  Top  15   55  

Execu&ve  Team  Dr  Richard  Hopkins  –  CEO  Dr  Paul  WaQ  -­‐  CSO  

Summary  

ASX   PYC  Cash  (9/14)   4.7m  Net  Burn   3.2m  Market  Cap   16m  52  wk  low/high   0.1/0.4c  Shares  on  issue   1000m  

Board  of  Directors  

Dr  Doug  Wilson  Non-­‐Execu7ve  Chairman  

Dr  Richard  Hopkins  CEO  

Jeremy  Curnock-­‐Cook  NED  

Dr  Bernard  Hockings  NED  

Bruce  McHarrie  NED  

For

per

sona

l use

onl

y

Phylogica:  focussed  on  intracellular  delivery  of  biologics  

CNS Delivery

Antimicrobials

Vaccines Cell penetrating peptides

5  

Intracellular Drug Delivery

Cancer

Differen7a7on   Product  Focus  

For

per

sona

l use

onl

y

Technology  Update  

For

per

sona

l use

onl

y

Majority  of  drug  targets  are  inside  cells  

§  PYC  addressing  unmet  need  to  deliver  biologic  drugs  inside  cells!  

Intracellular  Drug  Targets  

Small  Molecule  Drugs  (10%)  

Undrugged  targets  (90%)  Biologics?  

For

per

sona

l use

onl

y

Pep7des:  purpose  built  for  the  job  

8  

Small  Molecule  Drugs  

Large  Biologics  (Smart  drugs)    

Size  

Targets  

Phylomer  Pep7des  

Cell  Penetra7ng  

Specific  (Biologic)  

For

per

sona

l use

onl

y

Cell  Penetra7ng  Phylomer  (CPPs):    delivering  biologics  cargoes  inside  cells  

9  

Poten7al  to  expand  the  druggable  landscape  by  >10-­‐fold!!  

For

per

sona

l use

onl

y

Valida7on  of    ‘Best  in  Class’  Phylomers  for  intracellular  drug  delivery  

10  

For

per

sona

l use

onl

y

‘Best-­‐in-­‐class’  Phylomers  for  delivering  drugs  inside  cells  

27/11/14   11  

HisMBP

PYC35_R

BD_S11

TAT_RBD_S

11

PYC-FPP-3_

RBD_S11

PYC-FPP-2_

RBD_S11

PYC-FPP-4_

RBD_S11

PYC-FPP-1_

RBD_S11

0

10

20

30

40

50%

gre

en v

iabl

e ce

lls (Q

3)si

ngle

cel

l pop

ulat

ion

10µM protein3µM protein

High  receptor-­‐expressing  cells:  transfec.on  efficiency:  70.3%  

‘Best  in  Class’  Phylomer  CPP  

Delivery  effi

cien

cy  

(%  Green

 Cells)  

25-­‐fold  

§  Phylomers  improve  intracellular  drug  deliver  25-­‐50  X  §  Phylomers  are  up  to  37-­‐X  befer  than  previous  cell  penetra.ng  gold  standard  

For

per

sona

l use

onl

y

Applica7ons  for  Phylogica’s    ‘Best-­‐in-­‐Class’  Drug  Deliver  Solu7on  

 

12  

For

per

sona

l use

onl

y

Mul7ple  commercialis7on  opportuni7es  

13  

Cell  Penetra.ng  Phylomers  

Improve  delivery  of  exis.ng  drugs    

‘Value  Adding’  

Plalorm     Products  

Fully  integrated  drug  delivery/discovery  plaTorm  

‘Phylomer  Therapeu?cs’  

For

per

sona

l use

onl

y

Value  Adding:  Approaching  key  potency  thresholds  

14  

10  µM  

1  µM  

0.1  µM  

Phylomer  CPPs_toxins  

<1µM  =  key  potency  threshold  

Amount  of  Drug  

Increasing  Drug  Ac

7vity

 

Phylomer  CPPs_cargoes  

Standard  CPP_Cargoes  

Compe7tors  

For

per

sona

l use

onl

y

Phylogica’s  Oncology  Programme      

Targe7ng  Breat  Cancer  

15  

For

per

sona

l use

onl

y

Developing  Phylomer    drugs  to  treat  cancer  

§  Unmet   need   for   drugs   against   breast   cancer   targets  intractable  to  conven.onal  therapies  

§  Phylogica’s  plaTorm  accelerates  path  to  drug  discovery  

§  Rapid  access  to  high-­‐value  commercial  inflexion  points  

16  

For

per

sona

l use

onl

y

Phylogica’s  Proprietary  Oncology  Programme  

Program   Indica7on   Discovery   Func7onal  Valida7on   Preclinical  

Stat  5/3   Breast  Cancer  

Myc   Breast  Cancer  

YB1    

Breast  Cancer    F

or p

erso

nal u

se o

nly

Upcoming  commercial  milestones  

§  Discovery  Partnerships  –  Genentech  II  (2014/15)  –  New  discovery  alliances  –  Cosmeceu.cal  out-­‐license  (Biolink)  

 

§  Oncology  programme  –  Early  2015:   In  vitro  data  –   important  early-­‐stage  partnering  opportunity.        

–  Late  2015:  In  vivo  data  -­‐    Licensing  opportunity  

18  

For

per

sona

l use

onl

y

A  Big  Thankyou  To  All  PYC  Staff!!!!!  

19  

For

per

sona

l use

onl

y

Summary  

§  World  leaders  in  pep.de-­‐based  intracellular  drug  delivery  

§  Combined  with  Phylogica’s  powerful  Drug  Discovery  technology  to  develop  fully-­‐integrated  drug  development  plaTorm  

 

§  Transi.oning  from  plaTorm  to  product  focussed  company  

§  Well   posi.oned   to   create   mul.ple   commercialisa.on  opportuni.es.  

20  

For

per

sona

l use

onl

y

Dr.  Paul  WaQ  Chief  Scien7fic  Officer  Tel:  +61  8  9489  7777  Fax:  +61  8  9489  7700  Mobile:  +61  421  550  213  paulw@phylogica.com  

Contact  Details  

21  

www.phylogica.com  

Dr.  Richard  Hopkins  Chief  Execu7ve  Officer  Tel:  +61  8  9489  7777  Fax:  +61  8  9489  7700  Mobile:  +61  405  656  868  richardh@phylogica.com  

For

per

sona

l use

onl

y